To make an appointment with a Valley cancer specialist,
please call 201-634-5339.
Home > Cancer Services > Research & Clinical Trials > Gastro-Intestinal Cancer

Gastro-Intestinal Cancer

Font ++ Click to Print

Identification of Genomic Biomarkers for Pre-Colonoscopy Screening Evaluation

Study Objectives: To find an alternative blood-based genomic biomarker panel as a pre-screening tool to colonoscopy. Once established, this pre-screening test, which is based on a simple blood test, can be used as the first-line screening tool to identify a high-risk segment of the general population, and to use a more extensive test (colonoscopy and others) on this subgroup to reduce incidence of colorectal cancer.

Principal Investigator: Ganepola Ganepola, M.D.



ATOMIC

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

This randomized phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.

Principal Investigator: Kevin Wood, M.D.

Click here for more information on ATOMIC



COMMIT

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient DNA mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab and atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Principal InvestigatorKevin Wood, M.D.


 

Identification of Proteomic and Nucleic Acid Biomarkers for Early Diagnosis of Pancreatic Cancer

Principal Investigator: Ganepola Ganepola, M.D.


 

M14-064

A Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab

Treatment Randomization:
  • Arm 1: ABT-165 plus FOLFIRI
  • Arm 2: Bevacizumab plus FOLFIRI

Key Eligibility Criteria:
  • Diagnosis of histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
  • At least 1 unresectable lesion on a computed tomography (CT) scan that is measurable as defined by RECIST, Version 1.1
  • ECOG 0-1
  • Progression following treatment with Fluoropyrimidine/oxaliplatin/bevacizumab-regimen in the metastatic setting Adequate hematologic, renal and hepatic function

Click here for more information on M14-064 

Principle Investigator: Kevin Wood, MD

The Valley Hospital Biorepository

For The Valley Hospital (TVH) patients undergoing surgical procedures, we offer the opportunity to participate in TVH Biorepository.  This protocol involves the freezing and storage of extra tissue not used for diagnosis, blood and other bodily fluids that may be used for future research designed to develop or contribute to generalized knowledge in cancer research. Available to all persons diagnosed with cancer, having surgery for excision, and is strongly encouraged.

Genomic research is currently being done at Valley on colon cancer and pancreatic cancer specimens with DNA arrays and proteomics.


Find a Doctor
 
View all physicians
Contact the Blumenthal Cancer Center

Have a question? Call 201-634-5339 or complete the form below. If you are experiencing a medical emergency, please call your doctor or emergency services provider.

(-
Retype the numbers below:
 Security code
----